biotech investing BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
biotech investing BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast Cancer
biotech investing BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ in Preclinical Cancer Models
biotech investing BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
biotech investing BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
biotech investing BriaCell to Present Positive Clinical Data for Bria-IMT and Preclinical Data for Next Generation Bria-OTS+ Personalized Immunotherapy at the 2026 AACR Conference
biotech investing BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
biotech investing BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
biotech investing BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
